Association between DRD2/ANKK1 Taq1A genotypes, depression and smoking cessation with nicotine replacement therapy

Stapleton, John; O’Gara, Colin; Spirling, Lucy I.; Ball, David

doi:10.1097/fpc.0b013e328347473a

Cited by 26 publications

(20 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Observed abstinence effect sizes for the most widely studied of these polymorphisms (rs1800497) suggested that NRT was more effective among persons with the A1/A1 or A1/A2 alleles and bupropion was more effective among persons with the A2/ A2 allele. These results are consistent with more recent trials that have also shown that persons with A1/A1 or A1/A2 genotypes have more favorable response to NRT patch (Breitling et al, 2011;Stapleton, Sutherland, O'Gara, Spirling, & Ball, 2011). Others have suggested a gene (ANKK1) × sex interaction (E. C. Yudkin et al, 2003) or gene (ANKK1) × gene (CYP2B6 or SLC6A3) interactions Lerman et al, 2003;Swan et al, 2007), but the limited state of the science in 2006 precluded these details from informing the design of the current pilot trial, which is aimed at understanding the psychological and behavioral impact of the GF as opposed to the efficacy of the genetically tailored treatment.…”

Section: Introductionsupporting

confidence: 92%

Pharmacogenetic Smoking Cessation Intervention in a Health Care Setting: A Pilot Feasibility Study

McClure

Swan

John

et al. 2012

Nicotine & Tobacco Research

View full text Add to dashboard Cite

show abstract

Section: Introductionsupporting

confidence: 92%

Pharmacogenetic Smoking Cessation Intervention in a Health Care Setting: A Pilot Feasibility Study

McClure

Swan

John

et al. 2012

Nicotine & Tobacco Research

View full text Add to dashboard Cite

show abstract

“…At the level of psychopathology, such comorbid relationships are more the rule than the exception, and may have more functional than etiological significance. Both behavioral and molecular genetic studies support the likelihood, however, that smoking/nicotine dependence and depression share at least some etiological features, including common genetic variance (e.g., Kendler et al 1993;Lyons et al 2008;McCaffery et al 2008) and, possibly, genes/genetic mechanisms (e.g., AudrainMcGovern et al 2004;Pergadia et al 2011;Stapleton et al 2011). While the nature of the genetic overlap is unclear at this point, it suggests that smoking-depression comorbidities are less likely to reflect superficial associations than they are to reflect meaningful 'proxies' for underlying common neurobiological endophenotypes.…”

Section: Discussionmentioning

confidence: 99%

“…Positive findings in both association (e.g., Audrain-McGovern et al 2004: Ishii et al 2011Stapleton et al 2011) and genetic linkage (Pergadia et al 2011) studies, however, are providing a promising foundation for future investigations.…”

Section: Molecular Genetics Of Smoking and Depressionmentioning

confidence: 99%

Genetics of smoking and depression

et al. 2012

View full text Add to dashboard Cite

Smoking and depression are significant public health problems with multiple etiological dimensions and outcomes. Although each condition is important by itself, they are important because they often potentiate each other. Consequently, it is also essential to understand the nature their relationship. This representative review focuses on the genetic etiology of the relationship in the context of reviewing first the epidemiology of depression and smoking, and then by exploring behavioral and molecular genetic studies, and other psychiatric and medical comorbidities. At this point, epidemiological evidence for a relationship between depression and smoking/nicotine dependence is compelling. Although behavioral genetic results differ somewhat by gender and in accordance with specific definitions of depression and smoking variables, recent studies show converging evidence for common genetic factors underlying the relationship, often in addition to non-shared environmental factors. The search for underlying genes and genetic mechanisms is at an early stage, but shows promising candidate genes and genetic approaches for future studies.

show abstract

“…Munafo et al (2009) later failed to replicate these findings in a larger cohort. Similar prospective trials have also failed to find a significant mediating effect of the Taq1A genotype on the efficacy of NRT in smoking cessation (Berlin et al, 2005; De Ruyck et al, 2010; Stapleton et al, 2011). …”

Section: Pharmacogenetics Of Drug Effects and Treatment Outcomementioning

confidence: 95%

A review of pharmacogenetic studies of substance-related disorders

Jones¹,

Comer²

2015

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Background Substance-related disorders (SRDs) are a major cause of morbidity and mortality worldwide. Family, twin, and adoption studies have demonstrated the substantial heritability of SRDs. To determine the impact of genetic variation on risk for SRD and the response to treatment, researchers have conducted a number of secondary data analyses and quasi-experimental studies that target one or more candidate gene variants. Methods This review examines studies in which candidate polymorphisms were examined as mediator variables to identify pharmacogenetic effects on subjective responses to drug administration or cues or outcomes of medication trials for SRDs. Efforts to use a meta-analytic approach to quantify these effects are premature because the number of available studies using similar methods and outcomes is limited, so the present review is qualitative. Results Findings from these studies provide preliminary evidence of clinically relevant pharmacogenetic effects. However, independent replication of these findings has been sparse. Conclusions Although this growing body of literature has produced conflicting results, improved statistical controls may help to clarify the findings. Additionally, the use of empirically derived sub-phenotypes (i.e., which serve to differentiate distinct groups of affected individuals) may also help to identify genetic mediators of pharmacologic response in relation to SRDs. The identification of genetic mediators can inform clinical care both by identifying risk factors for SRDs and predicting adverse events and therapeutic outcomes associated with specific pharmacotherapies.

show abstract

Association between DRD2/ANKK1 Taq1A genotypes, depression and smoking cessation with nicotine replacement therapy

Cited by 26 publications

References 35 publications

Pharmacogenetic Smoking Cessation Intervention in a Health Care Setting: A Pilot Feasibility Study

Pharmacogenetic Smoking Cessation Intervention in a Health Care Setting: A Pilot Feasibility Study

Genetics of smoking and depression

A review of pharmacogenetic studies of substance-related disorders

Contact Info

Product

Resources

About